Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01326702 · OUTCOME

Duration of Remission (Phase IIa)

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · Source last updated 2019-12-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
From the first documented response to the first documented progression or death, assessed up to 30 days post-treatment

Analysis population: Data were not collected

Groups in this outcome

Dose Level 1: Bendamustine 70 mg/m2, ABT-888 50 mg

Bendamustine 70 mg/m2, ABT-888 50 mg

Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg

Bendamustine 90 mg/m2, ABT-888 50 mg

Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID

Bendamustine 90 mg/m2, ABT-888 100 mg BID

Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID

Bendamustine 90 mg/m2, ABT-888 150 mg BID

Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID

Bendamustine 90 mg/m2, ABT-888 200 mg BID

Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID

Bendamustine 90 mg/m2, ABT-888 300 mg BID

Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID

Bendamustine 90 mg/m2, ABT-888 400 mg BID

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Level 1: Bendamustine 70 mg/m2, ABT-888 50 mg0
Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg0
Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID0
Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID0
Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID0
Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID0
Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      0
    4. group Id
      OG003
      value
      0
    5. group Id
      OG004
      value
      0
    6. group Id
      OG005
      value
      0
    7. group Id
      OG006
      value
      0
    units
    Participants
groups
  1. description
    Bendamustine 70 mg/m2, ABT-888 50 mg
    id
    OG000
    title
    Dose Level 1: Bendamustine 70 mg/m2, ABT-888 50 mg
  2. description
    Bendamustine 90 mg/m2, ABT-888 50 mg
    id
    OG001
    title
    Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg
  3. description
    Bendamustine 90 mg/m2, ABT-888 100 mg BID
    id
    OG002
    title
    Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID
  4. description
    Bendamustine 90 mg/m2, ABT-888 150 mg BID
    id
    OG003
    title
    Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID
  5. description
    Bendamustine 90 mg/m2, ABT-888 200 mg BID
    id
    OG004
    title
    Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID
  6. description
    Bendamustine 90 mg/m2, ABT-888 300 mg BID
    id
    OG005
    title
    Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID
  7. description
    Bendamustine 90 mg/m2, ABT-888 400 mg BID
    id
    OG006
    title
    Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID
population Description
Data were not collected
reporting Status
POSTED
time Frame
From the first documented response to the first documented progression or death, assessed up to 30 days post-treatment
title
Duration of Remission (Phase IIa)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice